We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacira BioSciences, Inc. (PCRX) - $25 value - yours FREE >>
Amarin Corporation PLC (AMRN) - $25 value - yours FREE >>
Anika Therapeutics Inc. (ANIK) - $25 value - yours FREE >>
ANI Pharmaceuticals, Inc. (ANIP) - $25 value - yours FREE >>
Image: Bigstock
Amarin (AMRN) Ends Patient Randomization in Vascepa Study
Amarin Corporation plc (AMRN - Free Report) announced that it has finished randomizing patients in the phase III REDUCE-IT study on a 1:1 basis between Vascepa (icosapent ethyl) and placebo.
REDUCE-IT will determine if Vascepa can reduce cardiovascular events in patients who have elevated triglyceride levels and other cardiovascular risk factors, despite stabilized statin therapy.
The primary endpoint includes the time of the first occurrence of the composite endpoint of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina, while secondary endpoints comprise the time to event analyses of components of the primary endpoint.
Onset of the final primary cardiovascular event is expected during the second half of 2017. Results from the study are anticipated in 2018.
Amarin stated that it expects a protocol pre-specified interim efficacy and safety analysis from an independent Data Monitoring Committee (DMC) this month. A second interim efficacy and safety analysis is anticipated in mid 2017.
AMARIN CORP PLC Price
AMARIN CORP PLC Price | AMARIN CORP PLC Quote
We note that in the U.S., Vascepa is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. In the first half of 2016, the company generated Vascepa sales of $58.1 million, up 74.5%.
For the full year, the company expects sales to be in the range of $112–$125 million.
Amarin currently has a Zacks Rank #2 (Buy). Some favorably placed stocks in the health care sector include Anika Therapeutics Inc. (ANIK - Free Report) , Pacira Pharmaceuticals, Inc. (PCRX - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . All three stocks sport a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>